Emmanuel S Antonarakis

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. doi request reprint Clinical problem-solving. Beware of first impressions
    Oluwaseun O Falade
    Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins School of Medicine, Baltimore 21224, USA
    N Engl J Med 359:628-34. 2008
  2. pmc Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231, USA
    Drug Des Devel Ther 5:117-24. 2011
  3. pmc Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
    Ali R Golshayan
    Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC, USA
    Core Evid 8:27-35. 2013
  4. pmc Immunotherapy for prostate cancer enters its golden age
    Sosipatros A Boikos
    Prostate Cancer Research Program, Johns Hopkins Sidney Kimmel Comp Cancer center, 1650 Orleans St CRB1 1M45, Baltimore, MD 21231
    Clin Med Insights Oncol 6:263-73. 2012
  5. pmc A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M45, Baltimore, MD 21231 1000, USA
    Cancer Chemother Pharmacol 71:883-92. 2013
  6. pmc Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M45, Baltimore, Maryland 21231 1000, USA
    Oncologist 18:163-73. 2013
  7. pmc The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Brady Urological Institute, Johns Hopkins University, Baltimore, MD 21231, USA
    BJU Int 109:32-9. 2012
  8. pmc Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, CRB1 1M45, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer 118:1533-42. 2012
  9. ncbi request reprint Targeting angiogenesis for the treatment of prostate cancer
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Prostate Cancer Research Program, Baltimore, MD 21231 1000, USA
    Expert Opin Ther Targets 16:365-76. 2012
  10. ncbi request reprint Future directions in castrate-resistant prostate cancer therapy
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Clin Genitourin Cancer 8:37-46. 2010

Collaborators

Detail Information

Publications50

  1. doi request reprint Clinical problem-solving. Beware of first impressions
    Oluwaseun O Falade
    Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins School of Medicine, Baltimore 21224, USA
    N Engl J Med 359:628-34. 2008
  2. pmc Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231, USA
    Drug Des Devel Ther 5:117-24. 2011
    ....
  3. pmc Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
    Ali R Golshayan
    Division of Hematology Oncology, Medical University of South Carolina, Charleston, SC, USA
    Core Evid 8:27-35. 2013
    ..Enzalutamide has demonstrated significant activity in men with metastatic CRPC...
  4. pmc Immunotherapy for prostate cancer enters its golden age
    Sosipatros A Boikos
    Prostate Cancer Research Program, Johns Hopkins Sidney Kimmel Comp Cancer center, 1650 Orleans St CRB1 1M45, Baltimore, MD 21231
    Clin Med Insights Oncol 6:263-73. 2012
    ....
  5. pmc A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M45, Baltimore, MD 21231 1000, USA
    Cancer Chemother Pharmacol 71:883-92. 2013
    ..We conducted a single-arm phase 2 study evaluating KX2-391 in men with chemotherapy-naïve bone-metastatic castration-resistant prostate cancer (CRPC)...
  6. pmc Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M45, Baltimore, Maryland 21231 1000, USA
    Oncologist 18:163-73. 2013
    ..We conducted a noncomparative, randomized, phase II study evaluating the antitumor efficacy of two doses of oral itraconazole in men with metastatic prostate cancer...
  7. pmc The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Brady Urological Institute, Johns Hopkins University, Baltimore, MD 21231, USA
    BJU Int 109:32-9. 2012
    ..To describe metastasis-free survival (MFS) in men with prostate-specific antigen (PSA) recurrence following radical prostatectomy, and to define clinical prognostic factors modifying metastatic risk...
  8. pmc Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, CRB1 1M45, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer 118:1533-42. 2012
    ..However, it is unknown whether changes in PSA kinetics influence metastasis-free survival (MFS)...
  9. ncbi request reprint Targeting angiogenesis for the treatment of prostate cancer
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Prostate Cancer Research Program, Baltimore, MD 21231 1000, USA
    Expert Opin Ther Targets 16:365-76. 2012
    ..The process of tumor angiogenesis is one target that is being exploited for therapeutic gain...
  10. ncbi request reprint Future directions in castrate-resistant prostate cancer therapy
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Clin Genitourin Cancer 8:37-46. 2010
    ..The future of CRPC therapy appears brighter than ever before...
  11. doi request reprint Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
    E S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Prostate Cancer Prostatic Dis 14:206-18. 2011
    ....
  12. pmc Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
    E S Antonarakis
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Prostate Cancer Prostatic Dis 14:192-205. 2011
    ....
  13. ncbi request reprint Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects
    Emmanuel S Antonarakis
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, CRB1 191, Baltimore, MD 21231, USA
    Expert Opin Investig Drugs 19:311-4. 2010
    ..These studies provide a rationale for designing clinical trials that combine low-dose cyclophosphamide with GM-CSF-secreting cell-based immunotherapy in patients with prostate and other cancers...
  14. pmc Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    BJU Int 108:378-85. 2011
    ....
  15. ncbi request reprint Orientation of the stethoscope around the neck: a random phenomenon or an indicator of cerebral lateralisation? Cross-sectional survey
    Emmanuel S Antonarakis
    Department of General Medicine, University Hospital of Wales, Cardiff, UK
    Laterality 11:287-93. 2006
    ..Stethoscope orientation preference is not a chance phenomenon and may be an expression of cerebral dominance...
  16. ncbi request reprint Not what it seems
    Emmanuel S Antonarakis
    Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Am J Med 120:408-11. 2007
  17. ncbi request reprint Novel targeted therapeutics for metastatic castration-resistant prostate cancer
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, United States
    Cancer Lett 291:1-13. 2010
    ....
  18. pmc An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy
    Emmanuel S Antonarakis
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer 118:6063-71. 2012
    ..The authors examined PTEN and additional protein markers in primary tumors from patients with high-risk, localized prostate cancer who received adjuvant docetaxel in a prospective multicenter trial (TAX2501)...
  19. pmc The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Prostate 71:1608-15. 2011
    ..We sought to determine the change of PSA doubling time (PSADT) and its association with disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer...
  20. pmc The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer
    Jatinder Goyal
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    BJU Int 110:E575-82. 2012
    ..After accounting for potential baseline inequalities, participation in a clinical trial itself was associated with significantly longer overall survival in these patients...
  21. pmc Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer
    Daniel J Zabransky
    Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    Prostate 72:487-98. 2012
    ....
  22. pmc Prostate angiosarcoma: is there any association with previous radiation therapy?
    Waseem Khaliq
    Departments of Medicine Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    BJU Int 110:E819-25. 2012
    ..Although radiation exposure has been suggested etiology of prostate angiosarcomas, assumption of such association is not supported by the current literature...
  23. doi request reprint Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Hum Vaccin Immunother 8:509-19. 2012
    ....
  24. pmc Management of patients with biochemical recurrence after local therapy for prostate cancer
    Channing J Paller
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M59, Baltimore, MD 21287, USA
    Hematol Oncol Clin North Am 27:1205-19, viii. 2013
    ..A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach. ..
  25. pmc Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy
    Emmanuel S Antonarakis
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Curr Opin Oncol 24:258-65. 2012
    ..In this article, we will summarize recent clinical data on several additional immune-directed strategies, some of which have now entered phase 3 trials...
  26. pmc Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, CRB1 1M59, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 69:763-71. 2012
    ..However, because of differences in antibody-dependent cellular cytotoxicity between AGS-PSCA and AGS-1C4D4, a limited Phase I trial using AGS-1C4D4 was performed evaluating safety and PK...
  27. pmc Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Eur J Cancer 47:1955-61. 2011
    ..Data suggests that they may inhibit tumourigenesis...
  28. pmc Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 11:14-23. 2013
    ..This review will summarize the acceptable standards of care for the management of biochemically recurrent prostate cancer, and will also outline some novel experimental approaches for the treatment of this disease state...
  29. pmc The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer
    Mario A Eisenberger
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, USA
    Urol Clin North Am 39:573-81. 2012
    ..These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials...
  30. doi request reprint Current status of immunological therapies for prostate cancer
    Emmanuel S Antonarakis
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Curr Opin Urol 20:241-6. 2010
    ..This review will discuss the most promising immune-directed strategies in development for prostate cancer, outlining interventions that mitigate tumor-induced tolerance and highlighting several combination immunotherapy approaches...
  31. pmc Current status of immunological approaches for the treatment of prostate cancer
    Charles G Drake
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Curr Opin Urol 22:197-202. 2012
    ....
  32. pmc Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 16:5269-76. 2010
    ..To evaluate the safety and activity of 6 months of treatment with lenalidomide at 5 or 25 mg/d in nonmetastatic biochemically relapsed prostate cancer...
  33. pmc Use of androgen deprivation therapy in prostate cancer: indications and prevalence
    Roisin M Connolly
    Prostate Cancer Research Program, Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Asian J Androl 14:177-86. 2012
    ..This review highlights the various androgen-directed treatment options available to men with prostate cancer, their specific indications and the evidence supporting each approach, as well as patterns of use of hormonal therapies...
  34. ncbi request reprint An atypical complication of atypical pneumonia
    Emmanuel S Antonarakis
    Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Am J Med 119:824-7. 2006
  35. pmc A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer
    Jianqing Lin
    Johns Hopkins University, Baltimore, MD 21231, USA
    Urol Oncol 31:581-8. 2013
    ..The objective of this study was to screen its clinical activity in patients with biochemically recurrent hormone-naïve prostate cancer...
  36. ncbi request reprint Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, and the Division of Oncology Biostatistics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 25:4998-5008. 2007
    ....
  37. pmc Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:4986-93. 2009
    ..We conducted a randomized, double-blind trial to examine the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy...
  38. ncbi request reprint Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Nat Clin Pract Oncol 6:12-3. 2009
    ..Multi-institutional, prospective trials should provide additional information on the tolerability and activity of this compound and further define the population most likely to benefit from this endocrine approach...
  39. pmc Tumorigenic potential of circulating prostate tumor cells
    Filipe L F Carvalho
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Oncotarget 4:413-21. 2013
    ..Only two of nine hosts grew TRAMP tumors and none of the human CTCs formed tumors, which suggests that most CTCs have relatively low tumor-forming potential. Future studies should identify and target the highly tumorigenic cells...
  40. doi request reprint Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
    Jatinder Goyal
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
    Cancer Lett 323:135-46. 2012
    ..This landmark finding will likely have a considerable impact on the treatment paradigm of bone-metastatic CRPC, and will pave the way for further developments in the future...
  41. pmc Surgical resection of malignant melanoma metastatic to the pancreas: case series and review of literature
    Jatinder Goyal
    Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 2101, USA
    J Gastrointest Cancer 43:431-6. 2012
    ..The aim of our study was to review our experience with the surgical resection of melanoma metastatic to the pancreas...
  42. ncbi request reprint Update: immunological strategies for prostate cancer
    Charles G Drake
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 410, Baltimore, MD, 21231, USA
    Curr Urol Rep 11:202-7. 2010
    ..Enthusiasm for prostate cancer immunotherapy is founded upon its potential to mediate targeted, specific, tumor cell destruction without significant systemic toxicity; however, this has yet to be fully realized in the clinical arena...
  43. doi request reprint Rheumatoid arthritis masked by docetaxel chemotherapy in a patient with ovarian carcinoma
    Marc A Callender
    Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland 21224, USA
    J Clin Rheumatol 14:121. 2008
  44. ncbi request reprint Ruthenium-based chemotherapeutics: are they ready for prime time?
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 191, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 66:1-9. 2010
    ....
  45. pmc Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer
    Sara Alcorn
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Int J Mol Sci 14:14800-32. 2013
    ..We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer. ..
  46. ncbi request reprint Prostate angiosarcoma: a case report and literature review
    Waseem Khaliq
    Department of Medicine, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, MFL Bldg, West Tower 6th Floor, Baltimore, MD 21224, USA
    Med Oncol 29:2901-3. 2012
    ..Only nine cases have been reported in the literature, and we report the 10th case of prostate angiosarcoma and the first case of prostate angiosarcoma with recurrent adenocarcinoma...
  47. ncbi request reprint Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Nat Clin Pract Urol 5:480-1. 2008
    ....
  48. ncbi request reprint A cut above
    Elisabeth B Marsh
    Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA
    Am J Med 120:1031-3. 2007
  49. ncbi request reprint Pemberton sign
    Emmanuel S Antonarakis
    Department of Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA
    Mayo Clin Proc 82:859. 2007